Global Search

Search articles, concepts, and chapters

OphthalmologyOctober 200735 citations

Adverse events after intravitreal triamcinolone in patients with and without uveitis.

Galor Anat, Margolis Ron, Brasil Oswaldo M F, Perez Victor L, Kaiser Peter K, Sears Jonathan E, Lowder Careen Y, Smith Scott D


AI Summary

This study found intravitreal triamcinolone causes more IOP elevation and cataract progression in uveitis patients, highlighting the need for close monitoring and risk counseling in this group.

Abstract

Purpose

To evaluate the rates of adverse ocular events after intravitreal triamcinolone acetonide (IVTA) injection in patients with and without uveitis.

Design

Retrospective observational case series.

Participants

Two hundred twenty-two eyes of 173 patients were included in the study: 45 eyes of 31 patients with macular edema (ME) due to uveitis and 177 eyes of 142 patients with ME secondary to other etiologies.

Methods

Retrospective review of patients who received IVTA at the Cole Eye Institute for ME attributable to various causes between the years 2001 and 2005. Data review of clinical records included patient demographics, etiology of ME, and adverse outcomes after injection. Rates of adverse outcomes in patients with and without uveitis were compared.

Main outcome measures

Intraocular pressure (IOP) elevation and posterior subcapsular cataract (PSC) progression.

Results

Uveitis patients were significantly younger, more likely to be female, and more likely to have had prior posterior sub-Tenon's capsule steroid injection and/or glaucoma therapy than their nonuveitis counterparts. In a multivariate analysis adjusting for the differences in these factors, the presence of uveitis was the strongest risk factor for an adverse IOP event (odds ratio, 2.5; 95% confidence interval [CI], 1.0-6.1; P = 0.05). The odds of having a documented increase in PSC after IVTA injection were 5.6 times greater in uveitis eyes (P = 0.007; 95% CI, 1.6-19.6).

Conclusions

Intraocular pressure elevation and PSC progression occurred with greater frequency in uveitis patients receiving IVTA. Patients with uveitis treated with IVTA should be counseled about these risks and monitored closely.


MeSH Terms

AgedCataractDisease ProgressionFemaleGlucocorticoidsHumansInjectionsIntraocular PressureLens Capsule, CrystallineMacular EdemaMaleMiddle AgedRetrospective StudiesRisk FactorsTriamcinolone AcetonideUveitisVisual AcuityVitreous Body

Is this article assigned to the wrong chapter(s)? Let us know.